和邦生物(603077.SH):公司全面復產
格隆匯10月9日丨和邦生物(603077.SH)公佈,公司於2020年8月20日發佈《和邦生物關於汛情對公司影響情況的公告》,公司受8.18洪水災害的影響,部分生產線停產,預計停產時間不會超過三個月。
2020年10月5日,在公司全體員工的不懈努力及設備供應商的積極支持下,受汛情影響的生產線已全面復產:
1.四川和邦生物科技股份有限公司母公司的90萬噸/年聯鹼生產線、草甘膦生產線全面復產;蛋氨酸生產線恢復到為投料試生產準備工作的最後階段;
2.樂山和邦農業科技有限公司的雙甘膦生產線全面復產;
3.公司全資子公司四川和邦鹽礦有限公司及樂山湧江實業有限公司的滷水及天然氣銷售也隨着公司全面復產恢復正常。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.